Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy

NCT01251861 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01251861
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01251861 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
March 17, 2011
Completion date
May 26, 2026
Enrollment
108 (actual)
Sites
198

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent prostate carcinoma, stage i prostate cancer ajcc v7, stage iia prostate cancer ajcc v7, stage iib prostate cancer ajcc v7, stage iii prostate cancer ajcc v7